Int J Med Sci
2022; 19(5):834-841.
doi:10.7150/ijms.71132 This issueCite
Research Paper
Real-world clinical outcomes of treatment with casirivimab-imdevimab among patients with mild-to-moderate coronavirus disease 2019 during the Delta variant pandemic
1. Department of Pulmonary Medicine, Fukushima Medical University, Fukushima, Japan 2. Department of Pulmonary Medicine, Ohara General Hospital, Fukushima, Japan 3. Department of Thoracic Surgery, Fukushima Red Cross Hospital, Fukushima, Japan 4. Department of Internal Medicine, Fujita General Hospital, Fukushima, Japan 5. Department of Pulmonary Medicine, Saiseikai Fukushima General Hospital, Fukushima, Japan 6. Department of General Internal Medicine and Clinical Infectious Diseases, Fukushima Medical University, Fukushima, Japan 7. Department of Internal Medicine, Saiseikai Kawamata Hospital, Fukushima, Japan 8. Department of Emergency and Critical Care Medicine, Aizu Chuo Hospital, Fukushima, Japan 9. Department of Infectious Disease and Pulmonary Medicine, Aizu Medical Center, Fukushima Medical University, Fukushima, Japan 10. Department of Internal Medicine, Takeda General Hospital, Fukushima, Japan 11. Department of Pediatric Medicine, Bange Kousei General Hospital, Fukushima, Japan 12. Department of Surgery, Yurin Hospital, Fukushima, Japan 13. Department of Pediatric Surgery, Iwaki City Medical Center, Fukushima, Japan 14. Department of Internal Medicine, Kashima Hospital, Fukushima, Japan 15. Department of Neurosurgery, Fukushima Rosai Hospital, Fukushima, Japan 16. Department of Emergency and Critical Care Medicine, Futaba Medical Center, Fukushima, Japan 17. Department of Internal Medicine, Soma General Hospital, Fukushima, Japan 18. Department of Pulmonary Medicine, Minami-Soma Municipal General Hospital, Fukushima, Japan 19. Department of Surgery, Onahama Chuo Clinic, Fukushima, Japan 20. Department of General Medicine, Shirakawa Satellite for Teaching and Research, Fukushima Medical University, Fukushima, Japan 21. Department of Cardiology and Vascular Medicine, Hoshi General Hospital, Fukushima, Japan 22. Department of Internal Medicine, Iwase General Hospital, Sukagawa, Japan 23. Department of Surgery, Southern TOHOKU General Hospital, Fukushima, Japan 24. Department of Pulmonary Medicine, Jusendo General Hospital, Fukushima, Japan 25. Department of Emergency and Critical Care Medicine, Ohta Nishinouchi Hospital, Fukushima, Japan 26. Department of Respiratory Medicine, Tsuboi Hospital, Fukushima, Japan 27. Department of Emergency and Critical Care Medicine, Fukushima Medical University, Fukushima, Japan
✉ Corresponding author: Yoko Shibata, MD, PhD. Address: Department of Pulmonary Medicine, Fukushima Medical University, School of Medicine, 1 Hikarigaoka, Fukushima City, Fukushima Prefecture, 960-1295, Japan. Tel: +81-24-547-1360 Fax: +81-24-548-9366 Email: shibatayac.jpMore
Citation:
Suzuki Y, Shibata Y, Minemura H, Nikaido T, Tanino Y, Fukuhara A, Kanno R, Saito H, Suzuki S, Ishii T, Inokoshi Y, Sando E, Sakuma H, Kobayashi T, Kume H, Kamimoto M, Aoki H, Takama A, Kamiyama T, Nakayama M, Saito K, Tanigawa K, Sato M, Kanbe T, Kanzaki N, Azuma T, Sakamoto K, Nakamura Y, Ohtani H, Waragai M, Maeda S, Ishida T, Sugino K, Tsukada Y, Yamada R, Sato R, Onuma T, Tomita H, Saito M, Watanabe N, Rikimaru M, Kawamata T, Umeda T, Morimoto J, Togawa R, Sato Y, Saito J, Kanazawa K, Iseki K. Real-world clinical outcomes of treatment with casirivimab-imdevimab among patients with mild-to-moderate coronavirus disease 2019 during the Delta variant pandemic. Int J Med Sci 2022; 19(5):834-841. doi:10.7150/ijms.71132. https://www.medsci.org/v19p0834.htm
Background: Mutations of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may reduce the efficacy of neutralizing monoclonal antibody therapy against coronavirus disease 2019 (COVID-19). We here evaluated the efficacy of casirivimab-imdevimab in patients with mild-to-moderate COVID-19 during the Delta variant surge in Fukushima Prefecture, Japan.
Methods: We enrolled 949 patients with mild-to-moderate COVID-19 who were admitted to hospital between July 24, 2021 and September 30, 2021. Clinical deterioration after admission was compared between casirivimab-imdevimab users (n = 314) and non-users (n = 635).
Results: The casirivimab-imdevimab users were older (P < 0.0001), had higher body temperature (≥ 38°C) (P < 0.0001) and greater rates of history of cigarette smoking (P = 0.0068), hypertension (P = 0.0004), obesity (P < 0.0001), and dyslipidemia (P < 0.0001) than the non-users. Multivariate logistic regression analysis demonstrated that receiving casirivimab-imdevimab was an independent factor for preventing deterioration (odds ratio 0.448; 95% confidence interval 0.263-0.763; P = 0.0023). Furthermore, in 222 patients who were selected from each group after matching on the propensity score, deterioration was significantly lower among those receiving casirivimab-imdevimab compared to those not receiving casirivimab-imdevimab (7.66% vs 14.0%; p = 0.021).
Conclusion: This real-world study demonstrates that casirivimab-imdevimab contributes to the prevention of deterioration in COVID-19 patients after hospitalization during a Delta variant surge.
Suzuki, Y., Shibata, Y., Minemura, H., Nikaido, T., Tanino, Y., Fukuhara, A., Kanno, R., Saito, H., Suzuki, S., Ishii, T., Inokoshi, Y., Sando, E., Sakuma, H., Kobayashi, T., Kume, H., Kamimoto, M., Aoki, H., Takama, A., Kamiyama, T., Nakayama, M., Saito, K., Tanigawa, K., Sato, M., Kanbe, T., Kanzaki, N., Azuma, T., Sakamoto, K., Nakamura, Y., Ohtani, H., Waragai, M., Maeda, S., Ishida, T., Sugino, K., Tsukada, Y., Yamada, R., Sato, R., Onuma, T., Tomita, H., Saito, M., Watanabe, N., Rikimaru, M., Kawamata, T., Umeda, T., Morimoto, J., Togawa, R., Sato, Y., Saito, J., Kanazawa, K., Iseki, K. (2022). Real-world clinical outcomes of treatment with casirivimab-imdevimab among patients with mild-to-moderate coronavirus disease 2019 during the Delta variant pandemic. International Journal of Medical Sciences, 19(5), 834-841. https://doi.org/10.7150/ijms.71132.
ACS
Suzuki, Y.; Shibata, Y.; Minemura, H.; Nikaido, T.; Tanino, Y.; Fukuhara, A.; Kanno, R.; Saito, H.; Suzuki, S.; Ishii, T.; Inokoshi, Y.; Sando, E.; Sakuma, H.; Kobayashi, T.; Kume, H.; Kamimoto, M.; Aoki, H.; Takama, A.; Kamiyama, T.; Nakayama, M.; Saito, K.; Tanigawa, K.; Sato, M.; Kanbe, T.; Kanzaki, N.; Azuma, T.; Sakamoto, K.; Nakamura, Y.; Ohtani, H.; Waragai, M.; Maeda, S.; Ishida, T.; Sugino, K.; Tsukada, Y.; Yamada, R.; Sato, R.; Onuma, T.; Tomita, H.; Saito, M.; Watanabe, N.; Rikimaru, M.; Kawamata, T.; Umeda, T.; Morimoto, J.; Togawa, R.; Sato, Y.; Saito, J.; Kanazawa, K.; Iseki, K. Real-world clinical outcomes of treatment with casirivimab-imdevimab among patients with mild-to-moderate coronavirus disease 2019 during the Delta variant pandemic. Int. J. Med. Sci. 2022, 19 (5), 834-841. DOI: 10.7150/ijms.71132.
NLM
Suzuki Y, Shibata Y, Minemura H, Nikaido T, Tanino Y, Fukuhara A, Kanno R, Saito H, Suzuki S, Ishii T, Inokoshi Y, Sando E, Sakuma H, Kobayashi T, Kume H, Kamimoto M, Aoki H, Takama A, Kamiyama T, Nakayama M, Saito K, Tanigawa K, Sato M, Kanbe T, Kanzaki N, Azuma T, Sakamoto K, Nakamura Y, Ohtani H, Waragai M, Maeda S, Ishida T, Sugino K, Tsukada Y, Yamada R, Sato R, Onuma T, Tomita H, Saito M, Watanabe N, Rikimaru M, Kawamata T, Umeda T, Morimoto J, Togawa R, Sato Y, Saito J, Kanazawa K, Iseki K. Real-world clinical outcomes of treatment with casirivimab-imdevimab among patients with mild-to-moderate coronavirus disease 2019 during the Delta variant pandemic. Int J Med Sci 2022; 19(5):834-841. doi:10.7150/ijms.71132. https://www.medsci.org/v19p0834.htm
CSE
Suzuki Y, Shibata Y, Minemura H, Nikaido T, Tanino Y, Fukuhara A, Kanno R, Saito H, Suzuki S, Ishii T, Inokoshi Y, Sando E, Sakuma H, Kobayashi T, Kume H, Kamimoto M, Aoki H, Takama A, Kamiyama T, Nakayama M, Saito K, Tanigawa K, Sato M, Kanbe T, Kanzaki N, Azuma T, Sakamoto K, Nakamura Y, Ohtani H, Waragai M, Maeda S, Ishida T, Sugino K, Tsukada Y, Yamada R, Sato R, Onuma T, Tomita H, Saito M, Watanabe N, Rikimaru M, Kawamata T, Umeda T, Morimoto J, Togawa R, Sato Y, Saito J, Kanazawa K, Iseki K. 2022. Real-world clinical outcomes of treatment with casirivimab-imdevimab among patients with mild-to-moderate coronavirus disease 2019 during the Delta variant pandemic. Int J Med Sci. 19(5):834-841.
This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.